EMAIL THIS PAGE TO A FRIEND

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

ARMc8 indicates aggressive colon cancers and promotes invasiveness and migration of colon cancer cells.


PMID 26081621

Abstract

Recent studies have implicated ARMc8 in promoting tumor formation in non-small cell lung cancer and breast cancer; however, so far, no studies have revealed the expression pattern or cellular function of ARMc8 in colon cancer. In this study, we used immunohistochemical staining to measure ARMc8 expression in 206 cases of colon cancer and matched adjacent normal colon tissue. Clinically important behaviors of cells, including invasiveness and migration, were evaluated after upregulation of ARMc8 expression in HT29 cells through gene transfection or downregulation of expression in LoVo cells using RNAi. We found that ARMc8 was primarily located in the membrane and cytoplasm of tumor cells, and its expression level was significantly higher in colon cancer in comparison to that in the adjacent normal colon tissues (p < 0.001). ARMc8 expression was closely related to TNM stage (p = 0.006), lymph node metastasis (p = 0.001), and poor prognosis (p = 0.002) of colon cancer. The invasiveness and migration capacity of HT29 cells transfected with ARMc8 were significantly greater than those of control cells (p < 0.001), while ARMc8 siRNA treatment significantly reduced cell invasion and migration in LoVo cells (p < 0.001). Furthermore, we demonstrated that ARMc8 could upregulate the expression of MMP7 and snail and downregulate the expression of p120ctn and α-catenin. Therefore, ARMc8 probably enhanced invasiveness and metastatic capacity by affecting these tumor-associated factors, thereby playing a role in enhancing the tumorigenicity of colon cancer cells. ARMc8 is likely to become a potential therapeutic target for colon cancer.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1406973
Anti-AKR1A1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA017919
Anti-AKR1A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA019649
Anti-AKR1A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA027734
Anti-AKR1A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA019041
Anti-ARMC9 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA026671
Anti-ARMC9 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1307051
ANTI-ARMC9(N-TERMINAL) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4501894
Anti-MMP-7, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB2500637
Anti-MMP7 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406133
Anti-MMP7 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV46075
Anti-MMP7 antibody produced in rabbit, IgG fraction of antiserum
SAB1410789
Anti-MMP7 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
EHU078841 MISSION® esiRNA, esiRNA human AKR1A1 (esiRNA1)
EMU000431 MISSION® esiRNA, esiRNA targeting mouse Armc9 (esiRNA1)
EHU077441 MISSION® esiRNA, esiRNA human ARMC9 (esiRNA1)
EMU046331 MISSION® esiRNA, esiRNA targeting mouse Akr1a4 (esiRNA1)
WH0010327M1
Monoclonal Anti-AKR1A1 antibody produced in mouse, clone 1A11-2A4, purified immunoglobulin, buffered aqueous solution